Bristol-Myers Squibb completes previously announced sale of global diabetes business to AstraZeneca
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced sale of its global diabetes business to AstraZeneca. Bristol-Myers Squibb received from AstraZeneca a payment of approximately $2.7 billion in connection with the closing, and will receive by mid-February, a $0.6 billion milestone payment from the recent U.S. approval of Farxiga (dapagliflozin).
Roche delivers strong 2013 results
- Details
- Category: Roche
Roche's Group sales rose 6% to 46.8 billion Swiss francs in 2013 as a result of strong demand for Roche's biologic medicines in the area of oncology, immunology and ophthalmology as well as for its clinical laboratory diagnostic products, especially immunoassays. This sales performance contributed significantly to an 8% increase in the Group's core operating profit and, combined with lower financing costs, a 10% rise in core earnings per share. IFRS net income rose 22% to 11.4 billion Swiss francs as a result of lower restructuring costs and the reversal of previous impairment charges.
UCB and Biogen Idec enter agreement to commercialize multiple sclerosis and hemophilia therapies in Asia
- Details
- Category: UCB
UCB and Biogen Idec today announced that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Pfizer reports fourth-quarter and full-year 2013 results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2013. As a result of the full disposition of Zoetis on June 24, 2013, the financial results of the Animal Health business are reported as a discontinued operation in the consolidated statements of income for full-year 2013, and fourth-quarter and full-year 2012.
Novartis recognized among world's most sustainable companies in Corporate Knights Global 100
- Details
- Category: Novartis
Novartis has been named among the 2014 Corporate Knights Global 100. Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World (Global 100) index at the World Economic Forum in Davos.
Bristol-Myers Squibb Reports fourth quarter and full year 2013 financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model.
Abbott reports fourth-quarter and full-year 2013 results
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2013. Fourth-quarter 2013 worldwide sales of $5.7 billion increased 3.3 percent on an operational basis, driven by Diagnostics and Medical Devices. On a reported basis, sales increased 0.4 percent, including an unfavorable 2.9 percent effect of foreign exchange.
More Pharma News ...
- AstraZeneca and Bristol-Myers Squibb Diabetes Alliance provides $5 million grant for American Diabetes Association's Pathway to Stop Diabetes
- Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
- MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
- Bayer and Peking University establish new research center for translational research and drug discovery in Beijing
- GSK adds detailed clinical trial data to multi-sponsor request system
- Bayer plans to acquire Norwegian pharmaceutical company Algeta
- Bristol-Myers Squibb to sell its global diabetes business